Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Lipoprotein (a): a new cardiovascular risk factor].

C Herbaut1

  • 1Service de Médecine Interne, C.I.U. Ambroise Paré, Mons.

Revue Medicale De Bruxelles
|May 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Cytochemical and ultrastructural study of oogenesis inLithobius forficatus L. (Myriapoda, Chilopoda). Evolution of cellular components].

Wilhelm Roux' Archiv fur Entwicklungsmechanik der Organismen·2017
Same author

Pearl formation: persistence of the graft during the entire process of biomineralization.

Marine biotechnology (New York, N.Y.)·2006
Same author

[Omega-3 and health].

Revue medicale de Bruxelles·2006
Same author

[Recent oral antidiabetic therapy].

Revue medicale de Bruxelles·2005
Same author

Pharmacokinetics of gliquidone, glibenclamide, gliclazide and glipizide in middle-aged and aged subjects.

Research communications in molecular pathology and pharmacology·1999
Same author

Long-term (1 year) acceptability of perindopril in type II diabetic patients with hypertension.

The American journal of medicine·1992

Lipoprotein(a) [Lp(a)] is an atherogenic particle linked to cardiovascular risk. Further research is needed to understand Lp(a) metabolism and its precise role in atherosclerosis development.

Area of Science:

  • Biochemistry
  • Cardiovascular Science
  • Molecular Biology

Context:

  • Lipoprotein(a) [Lp(a)] is a distinct lipoprotein particle composed of low-density lipoprotein (LDL) and apolipoprotein(a) (apo(a)).
  • Apolipoprotein(a) shares structural similarities with plasminogen, a key protein in the blood clotting cascade.
  • Clinical evidence suggests Lp(a) possesses significant atherogenic properties, contributing to the development of atherosclerosis.

Purpose:

  • To elucidate the metabolic pathways of Lipoprotein(a) [Lp(a)].
  • To identify the specific mechanisms underlying the atherogenic effects of Lp(a).

Summary:

  • Lp(a) is an LDL particle with an attached apo(a) glycoprotein.
  • Apo(a) shares features with plasminogen, hinting at potential roles in both lipid metabolism and thrombosis.

Related Experiment Videos

  • Despite clinical data indicating atherogenicity, the exact metabolism and causative mechanisms of Lp(a) remain largely unknown.

    • Impact:

    • Understanding Lp(a) metabolism and atherogenic mechanisms is crucial for accurate cardiovascular risk assessment.
    • Widespread Lp(a) measurement could significantly enhance the prediction and management of cardiovascular diseases.
    • This knowledge gap highlights the need for further investigation into Lp(a) as a therapeutic target.